AMD

A new study described the underlying defect responsible for development of AMD and related macular dystrophies (MDs).

Socioeconomic factors have long been a looming issue in various health outcomes. A team of researchers from Shanghai Jiao Tong University School of Medicine and Fudan University set out to review the impact of socioeconomic status inequality on the incidence of AMD.

The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and Emerging Therapies.

The PPQ campaign consisted of the production of 3 successful consecutive commercial-scale drug substance batches required for the validation of Opthea’s manufacturing process.

4D Molecular Therapeutics has announced data based on the longest interim follow-up from Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design.

Gene therapy offers a promising alternative by potentially providing long-lasting effects from a single treatment.

Research by investigators at Trinity College in Dublin shows how the gene therapy conferred significant benefit in animal models, and in human cells derived from people with glaucoma.

This certification covers AI based regulatory requirements for the company's platform for AI imaging and diagnostic tools.

Data from this trial will be reported ahead of AAO 2024 in Chicago, Illinois.

InMed Pharmaceuticals has been issued 3 US patents, one of which is for an ocular drug delivery formulation for potential use in AMD.

The next step for the research likely will focus on determining whether blocking GSK3 can reverse existing AMD damage, potentially leading to new treatment options.

According to the company, the pre-clinical safety and efficacy studies of its product have yielded positive results in 3 internationally recognized labs in India, Singapore and the United States.

According to the company, the FDA approval strengthens its biosimilar position in the US market.

The CPT code is the first to report photobiomodulation therapy in retinal disease.

The SOL-R clinical trial of is deemed appropriate for use as Ocular Therapeutix’s second adequate and well controlled study of axitinib intravitreal implant.

According to the company, the wearable smart glasses with both vision enhancement and assistance will be introduced at the American Retina Forum National Meeting

LUBT010 is a ranibizumab biosimilar to Lucentis that achieved its primary endpoint in this study.

The company is developing ixoberogene soroparvovec, its clinical-stage gene therapy product candidate, for the treatment of wet AMD.

According to the researchers, the findings suggest drusen formation is a downstream effect of AKT2-related lysosome dysfunction and points to a new target for therapeutic intervention.

The trial will evaluate repeat dosing of axitinib intravitreal implant, (AXPAXLI) for the treatment of patients with wet AMD.

Charles Wykoff, MD, PhD, gives an insight into first-time data from the phase 2, LUNA trial looking at Ixo-Vec at the annual ASRS meeting in Stockholm, Sweden.

Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden.

According to the company, its implantable miniature telescope is a Galilean intraocular telescope designed to improve visual acuity and quality of life for patients with late-stage AMD.

Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.